Dr Reddy's Labs
Dr Reddy's Labs Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Dr. Despite the current supply setback with semaglutide, Dr.
From Dr Reddy's Labs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Dr. Reddy's expects to supply 6 to 7 million semaglutide pens between Q3 and Q4 of FY27, despite a delay caused by API scale-up validation issues.
- The original annual target was 12 million pens in the first year of launch; the delay means this target may be missed but does not reflect a drop in demand.
- Demand remains robust, outstripping supply, with no anticipated decrease, despite competitive pressure.
- Plans for in-house captive manufacturing remain on track, albeit with a delay of a few months beyond prior timelines.
- Long-term partnership with OneSource continues, supporting a reliable supply chain for many years.
- No immediate regulatory impacts or recalls affecting market supplies; the supply issue is temporary with resolution expected by September-October 2026.
- EBITDA margin targets of 20%+ remain unchanged aside from the temporary setback.
Profitability & Margins
See what Dr Reddy's Labs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Dr. Reddy's is progressing with plans for captive manufacturing of semaglutide to supplement supply from OneSource.
- There is no change to these plans despite the current impurity-related manufacturing delays.
- The in-house facility will require API validation before full-scale production, causing a potential delay of a few months beyond original timelines.
- The company plans to maintain a long-term relationship with OneSource alongside their own manufacturing capacity.
- The in-house manufacturing facility will support semaglutide as well as other products, indicating strategic capital investment in expanding manufacturing capabilities.
- No specific CAPEX figures or timelines were disclosed in the call transcript related to these investments.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Reddy's Labs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Dr. Reddy's is currently facing a temporary supply halt for semaglutide injection due to an impurity issue detected in scale-up API batches.
- The company expects to resolve the issue and resume commercial supply by late October to early November 2026.
- They anticipate supplying approximately 6 to 7 million semaglutide pens between Q3 and Q4 of fiscal year 2027.
- This supply estimate reflects a shortened selling window compared to the original full-year target of 12 million pens.
- The firm is committed to a long-term partnership with OneSource for supply alongside their own manufacturing facilities.
- No penalties or failure-to-supply fees are expected with partners due to the delay.
- Alternate API suppliers are being qualified but are expected to be operational only after about a year, not aiding the near-term supply constraint.
Dr Reddy's Labs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹7.5K Cr, net profit ₹221 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Reddys Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Dr Reddy's Labs Q1 FY27 results?
Dr. Despite the current supply setback with semaglutide, Dr.
What is Dr Reddy's Labs share price analysis?
Dr Reddy's Labs currently shows a below-average growth signal. The stock trades at a P/E of 30.4 with a market cap of ₹98,049 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Reddy's Labs planning capital expenditure?
Dr.
Keep Dr Reddy's Labs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.